Verastem VSTM Stock Price, Company Overview & News

vstm stock price today
vstm stock price today

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. Long term indicators fully support a continuation of the trend. Realtime quote and/or trades are not sourced from all markets.

Live educational sessions using site features to explore today’s markets. CUP AND HANDLE FORMING NEW PT 6.50+Price above 200 EMA. There may be delays, omissions, or inaccuracies in the Information. As an investor, you want to buy stocks with the highest probability of success.

What is the price target for VSTM?

Verastem Inc (NASDAQ:VSTM)

The 6 analysts offering 12-month price forecasts for Verastem Inc have a median target of 4.00, with a high estimate of 5.50 and a low estimate of 3.00. The median estimate represents a +735.07% increase from the last price of 0.48.

U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill database wallpapers investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). You can find your newly purchased Verastem stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets.

Insider Trades

If you had invested in Verastem stock at $11.09, your return over the last 11 years would have been -96.12%, for an annualized return of -25.58% . Overall, this stock passed 12/33 due dilligence checks and has average fundamentals, according to our automated analysis. Wainwright H.C. Wainwright analyst Sean Lee lowered the firm’s price target on Verastem to $3 from $5 and keeps…

What does Verastem do?

Media Resources. Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers.

Real-time quotes, advanced visualizations, backtesting, and much more. All values as of most recently reported quarter unless otherwise noted. There is no website visitor data available for this stock. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revenue and Earnings Metrics

These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public may earn fees when you purchase or sell Alternative Assets.

  • These three low-priced cancer stocks could be grossly undervalued.
  • This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
  • My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market’s returns over the past century!
  • When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“).

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer.

Trading Expectations (VSTM) For The Upcoming Trading Day Of Thursday 16th

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

Market cap is the total market value of a publicly traded company’s outstanding shares. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

VSTM Verastem Inc

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. In the past three months, Verastem insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $443.00 in company stock. Verastem has only been the subject of 2 research reports in the past 90 days. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Verastem has been upgraded to a Zacks Rank #1 , reflecting growing optimism about the company’s earnings prospects.

Is Verastem Inc.’s (NASDAQ: VSTM) Stock Due For A Strong Run? – Marketing Sentinel

Is Verastem Inc.’s (NASDAQ: VSTM) Stock Due For A Strong Run?.

Posted: Mon, 13 Mar 2023 15:32:05 GMT [source]

Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Robert Forrester has an approval rating of 100% among the company’s employees.

Research Report for VSTM

On corrections up, there will be some resistance from the lines at $0.432 and $0.558. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 03, 2023, and so far it has fallen -39.02%. Further fall is indicated until a new bottom pivot has been found. Volume fell on the last day without any changes to the price.

vstm stock price today

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).

Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details.

Is VSTM a good buy?

Out of 3 analysts, 1 (33.33%) are recommending VSTM as a Strong Buy, 2 (66.67%) are recommending VSTM as a Buy, 0 (0%) are recommending VSTM as a Hold, 0 (0%) are recommending VSTM as a Sell, and 0 (0%) are recommending VSTM as a Strong Sell.

The company’s pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase inhibition. Verastem stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. The low in the last 52 weeks of Verastem stock was 0.29. According to the current price, Verastem is 154.40% away from the 52-week low. The high in the last 52 weeks of Verastem stock was 2.13.

According to analysts’ consensus price target of $4.25, Verastem has a forecasted upside of 849.1% from its current price of $0.45. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction. VSTM climbed in early trading after boosting the size of its deal. The company’s stock opened at $11 a share on the Nasdaq, up from its initial public offering price of $10… The Verastem stock holds several negative signals and despite the positive trend, we believe Verastem will perform weakly in the next couple of days or weeks.

vstm stock price today

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

vstm stock price today

This does not cause any direct divergence but may be an early warning and a possible “turning point”. Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors. George Budwell Normally, companies with share prices lower than $5 — commonly called penny stocks — wouldn’t even be worth a glance. According to 12 analysts, the average rating for VSTM stock is “Buy.” The 12-month stock price forecast is $4.16, which is an increase of 830.65% from the latest price. 3 Monster Growth Stocks That Could Reach New Highs Let’s talk about growth stocks. These are stocks that have shown strong and sustained share price appreciation, sometimes…

What does Verastem do?

Media Resources. Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers.